Xinsong Chen
About me
A researcher with years of experience and verifiable achievements in oncology, experimental pathology, cell and molecular biology, tumor biology, and virology from leading laboratories at Karolinska Institutet (KI). Currently, I am working as a research specialist (senior scientist) at the Oncology-Pathology department of KI and Karolinska University Hospital, with the main focus on studying breast cancer biomarkers, establishing novel diagnostic approaches for improving patient segmentation, precision oncology using various sequencing base tools, and developing various cancer patient biopsies-based IVD assays for better prediction of treatment response and facilitate drug development. I also participated in the preparation and management of several clinical trial translational studies.
Research
My primary research interests are studying intra-tumoral heterogeneity using multi-omics datasets and multi-modality approaches, precision medicine &
- diagnostics for breast cancer patients, as well as translational medicine studies from clinical trials or patient cohorts.
Teaching
Course supervisor and thesis examiner for 5 master’s students at the Biomedicine program KI.
Co-supervisor for 3 Ph.D. students at Dept. Oncology-Pathology, KI.
Lecturing undergraduate to Ph.D. level courses at KI including: Basic Tumor Biology, Basic Tumor Histopathology, Molecular Pathology, Molecular Medicine - Oncology.
Articles
- Article: NATURE COMMUNICATIONS. 2024;15(1):9343
- Article: GENOME BIOLOGY. 2024;25(1):214
- Article: SCIENCE TRANSLATIONAL MEDICINE. 2024;16(747):eadi2952
- Article: BIOINFORMATICS. 2024;40(5):btae284
- Article: JOURNAL OF EXPERIMENTAL AND CLINICAL CANCER RESEARCH. 2024;43(1):107
- Article: BREAST CANCER RESEARCH. 2024;26(1):24
- Article: SCIENCE. 2023;382(6675):1137
- Article: BIOENGINEERING & TRANSLATIONAL MEDICINE. 2023;8(5):e10537
- Article: NATURE BIOTECHNOLOGY. 2023;41(8):1085-1088
- Article: NATURE COMMUNICATIONS. 2023;14(1):982
- Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2023;120(1):e2209856120
- Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2022;10(5):e004592
- Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2021;22(3):1354
- Article: BREAST CANCER RESEARCH. 2020;22(1):80
- Article: CANCER RESEARCH. 2020;80(7):1538-1550
- Article: JOURNAL OF CLINICAL INVESTIGATION. 2020;130(3):1185-1198
- Article: ONCOGENE. 2016;35(29):3807-3816
- Article: ONCOGENE. 2013;32(49):5522-5530
- Article: PLOS PATHOGENS. 2013;9(10):e1003664
All other publications
- Conference publication: CANCER RESEARCH. 2024;84(9):po4-01-05-po4-01-05
- Conference publication: VIRCHOWS ARCHIV. 2024;485:S206
- Letter: CANCER COMMUNICATIONS. 2023;43(7):855-859
- Meeting abstract: CANCER RESEARCH. 2023;83(5):p2-21-02-p2-21-02
- Preprint: BIORXIV. 2022
- Meeting abstract: ANNALS OF ONCOLOGY. 2022;33(7):S1306
- Preprint: BIORXIV. 2022
- Conference publication: VIRCHOWS ARCHIV. 2018;473:S30
- Thesis / dissertation: 2015
- Review: SEMINARS IN CANCER BIOLOGY. 2014;26:43-51
Selected grants
- Precision pathology - prediction of patient specific drug responseRegion Stockholm (Health, Medicine and Technic)1 January 2022 - 31 December 2024
- Treatment Prediction and heterogeneity studies on breast cancer using ex vivo modelsKarolinska Institutet Foundations20 October 2020 - 20 October 2022
Grants
- Investigating intratumoral heterogeneity to improve treatment outcomeCancerfonden1 January 2024 - 31 December 2026
Employments
- Research Specialist, Department of Oncology-Pathology, Karolinska Institutet, 2022-
Degrees and Education
- PhD Of Medical Science, Department of Cell and Molecular Biology, Karolinska Institutet, 2015
Journal reviewing
- npj Precision Oncology, Nature Portfolio, Anonymous peer review
- Advanced Science, Wiley, Anonymous peer review